0000000000942849

AUTHOR

Niccolò Bolli

showing 2 related works from this author

CD40 activity on mesenchymal cells negatively regulates OX40L to maintain bone marrow immune homeostasis under stress conditions

2021

BackgroundWithin the bone marrow (BM), mature T cells are maintained under homeostatic conditions to facilitate proper hematopoietic development. This homeostasis depends upon a peculiar elevated frequency of regulatory T cells (Tregs) and immune regulatory activities from BM-mesenchymal stem cells (BM-MSCs). In response to BM transplantation (BMT), the conditioning regimen exposes the BM to a dramatic induction of inflammatory cytokines and causes an unbalanced T-effector (Teff) and Treg ratio. This imbalance negatively impacts hematopoiesis, particularly in regard to B-cell lymphopoiesis that requires an intact cross-talk between BM-MSCs and Tregs. The mechanisms underlying the ability of…

mesenchymal cellAdultMaleCancer ResearchTransplantation ConditioningT cellbone marrow transplantationImmunologyBone Marrow CellsOX40 LigandBiologySettore MED/08 - Anatomia PatologicaLymphocyte ActivationMesenchymal Stem Cell TransplantationT-Lymphocytes RegulatoryMiceYoung AdultImmune systemBone MarrowStress PhysiologicalmedicineCD40AnimalsHomeostasisHumansImmunology and AllergyLymphopoiesisCD40 AntigensOriginal ResearchAgedCD40B-cell developmentMesenchymal Stem Cellshemic and immune systemsRC581-607Middle AgedOX40LCell biologyTransplantationHaematopoiesismedicine.anatomical_structureGene Expression Regulationbiology.proteinFemaleBone marrowImmunologic diseases. AllergyStem cellB-cell developmentbone marrow transplantation CD40 mesenchymal cell OX40L
researchProduct

Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

2022

The treatment scenario for newly-diagnosed transplant-ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiD) +/- the monoclonal antibody Daratumumab are used for first-line treatment, even if head-to-head comparisons are lacking. To compare efficacy and safety of these regimens, we performed a network meta-analysis (NMA) of 27 phase 2/3 randomized trials including a total of 12935 patients and 23 different schedules. Four efficacy/outcome and one safety indicators were extracted and integrated to obtain (for each treatment) the surface under the cumulative ranking-curve (SUCRA), a metric use…

multiple myelomaCancer ResearchOncologyprincipal component analysisnon-transplant eligibleI line treatment multiple myeloma network meta-analysis non-transplant eligible principal component analysisHematologyGeneral MedicineSettore MED/15 - Malattie del SangueI line treatmentnetwork meta-analysisI line treatment; multiple myeloma; network meta-analysis; non-transplant eligible; principal component analysis;
researchProduct